SCHEMBL5019657

SCHEMBL5019657

CN(C)CCCCNC(=O)CCc1ccccc1Sc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.51
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
BLM P54132 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NOD2 Q9HC29 1/20 0.45
CCR2 P41597 2/20 0.44
POLB P06746 1/20 0.43
ACKR3 P25106 1/20 0.43
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ITGB2 P05107 2/20 0.41
ICAM1 P05362 2/20 0.41
ITGAL P20701 2/20 0.41
SLC6A9 P48067 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23666455 0.92 SLC6A4 (0.54) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL10330281 0.90 ACKR3 (0.43) SLC6A4ALDH1A1LMNACCR2ACKR3
SCHEMBL6763799 0.88 LMNA (0.47) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6761155 0.87 LMNA (0.46) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6762149 0.87 LMNA (0.48) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6762867 0.86 LMNA (0.46) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6761995 0.86 LMNA (0.47) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6759484 0.84 LMNA (0.44) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6766233 0.83 LMNA (0.45) SLC6A4ALDH1A1LMNABLMNPSR1
SCHEMBL6763050 0.82 LMNA (0.42) SLC6A4ALDH1A1LMNABLMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050181066-A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency ALTANA PHARMA AG (DE) 2005-08-18 US claimed
EP-1501605-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA Pharma AG (DE) 2005-02-02 EP claimed
WO-2003090870-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA PHARMA AG (DE) 2003-11-06 WO claimed
EP-3538096-B1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2023-11-30 US disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
EP-3481820-B1 SOLID FORMS OF AN SGC STIMULATOR CYCLERION THERAPEUTICS INC (US) 2023-10-18 EP disclosed
US-11731977-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
EP-3872080-B1 FUSED BICYCLIC SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-08-16 EP disclosed
US-11690828-B2 Treatment of CNS diseases with sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
WO-2023018795-A1 NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS CURTAILS LLC (US) 2023-02-16 WO disclosed
WO-2014047111-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2014-03-27 WO disclosed
US-20130178475-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-07-11 US disclosed
US-20130178475-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-07-11 US disclosed
WO-2013101830-A1 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-07-04 WO disclosed
WO-2012064559-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-05-18 WO disclosed
WO-2011115804-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-09-22 WO disclosed
US-20050181066-A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency ALTANA PHARMA AG (DE) 2005-08-18 US disclosed
EP-1501605-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA Pharma AG (DE) 2005-02-02 EP disclosed
WO-2003090870-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA PHARMA AG (DE) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178475-A1 sGC STIMULATORS GUCY1A1, PTGIS, GUCY1B1 SLC6A4 3918/4885ALDH1A1 1325/4885LMNA 3689/4885
US-11690828-B2 Treatment of CNS diseases with sGC stimulators GUCY1A2, GUCY1B2, PDE2A SLC6A4 1231/4885ALDH1A1 3866/4885LMNA 4287/4885
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1B2, PDE2A SLC6A4 1231/4885ALDH1A1 3866/4885LMNA 4287/4885
US-11731977-B2 SGC stimulators GUCY1A2, PRKG1, GMPS SLC6A4 3549/4885ALDH1A1 2650/4885LMNA 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.